Skip to main content

Table 2 Criteria for Disease Activity

From: The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study

1. A loss of VA ≥5 letters than the best VA recorded since baseline.

2. New retinal haemorrhage.

3. The presence of IRF or SRF on OCT.

 For patients in the Intensive retinal fluid arm, this criterion is “the presence of any IRF or SRF”.

 For patients in the Relaxed retinal fluid arm, this criterion is “the presence of any IRF or SRF >200 μm in height at subfoveal centre” (as measured by the caliper function on the OCT). Sub-RPE fluid does not constitute part of the decision-making criteria for either arm.